Acute Heart Failure Comorbidome: The Impact of Everything Else

Comorbidoma na Insuficiência Cardíaca Aguda: O Impacto de Tudo o Resto

Mariana Alves MEIRELES*, João GONÇALVES†, João NEVES†

ABSTRACT

Introduction: Heart failure frequently coexists with several comorbidities. Our aim is to evaluate the prognostic role of various comorbidities in the risk of acute heart failure development.

Material and Methods: Comorbidities of patients with acute heart failure were, retrospectively, compared to a control group of patients with chronic heart failure admitted to an Internal Medicine unit in a 2-year period. Logistic regression models were constructed to determine their association with acute heart failure and to develop a comorbidome.

Results: We identified 229 patients with acute heart failure and 201 patients with chronic heart failure. Age and female gender were higher in acute heart failure group (p < 0.001) as was the number of comorbidities (4.0 ± 3.0 vs 4.0 ± 2.0, p = 0.044). Hyperuricemia (odds ratio 2.46, confidence interval 95% 1.41 - 4.31, p = 0.002), obesity (odds ratio 2.22, confidence interval 95% 1.31 - 3.76, p = 0.003), atrial fibrillation (odds ratio 1.93, confidence interval 95% 1.31 - 2.87, p = 0.001), peripheral artery disease (odds ratio 2.12, confidence interval 95% 1.01 - 4.42, p = 0.046) and chronic kidney disease (odds ratio 2.47, confidence interval 95% 1.65 - 3.71, p < 0.001) were associated with acute heart failure. Obesity, atrial fibrillation, peripheral artery disease and chronic kidney disease were identified as independent risk factors. Patients with multiple comorbidities had a superior risk of hospitalization due to heart failure: zero comorbidities – odds ratio 0.43, 95% confidence interval 0.28 - 0.67, p < 0.001; one comorbidity – odds ratio 0.69, 95% confidence interval 0.47 - 1.01, p = 0.057; two comorbidities – odds ratio 1.85, 95% confidence interval 1.11 - 3.08, p = 0.019; ≥ three comorbidities – odds ratio 5.81, 95% confidence interval 2.77 - 12.16, p < 0.001.

Discussion: This study shows an association between several comorbidities and hospital admission due to acute heart failure. The association seems to strengthen in the presence of multiple comorbidities.

Conclusion: A comorbidome is a useful tool to identify comorbidities associated with higher risk of acute heart failure. The identification of vulnerable patients may allow multidimensional interventions to minimize future hospital admissions.

Keywords: Heart Failure; Hospitalization; Comorbidity; Mortality

RESUMO

Introdução: A insuficiência cardíaca frequentemente coexiste com diversas comorbilidades. O nosso objetivo é avaliar o valor prognóstico de diferentes comorbilidades no risco de desenvolvimento de insuficiência cardíaca aguda.

Material e Métodos: As comorbilidades dos doentes com insuficiência cardíaca aguda foram, retrospectivamente, comparadas com um grupo controlo de doentes com insuficiência cardíaca crónica admitidos numa unidade de Medicina Interna no período de dois anos. Modelos de regressão logística foram construídos para determinar as comorbilidades associadas a insuficiência cardíaca aguda e para a construção do comorbidoma.

Resultados: Foram identificados 229 doentes com insuficiência cardíaca aguda e 201 com insuficiência cardíaca crónica. A idade e gênero feminino foram superiores no grupo insuficiência cardíaca aguda (p < 0.001), tal como o número de comorbilidades (4,0 ± 3,0 vs 4,0 ± 2,0, p = 0,044). A hiperuricemia (odds ratio 2,46, intervalo confiança 95% 1,41 – 4,31, p = 0,002), a obesidade (odds ratio 2,22, intervalo confiança 95% 1,31 – 3,76, p = 0,003), a fibrilação auricular (odds ratio 1,93, intervalo confiança 95% 1,31 – 2,87, p = 0,001), a doença arterial periférica (odds ratio 2,12, intervalo confiança 95% 1,01 – 4,42, p = 0,046) e a doença renal crónica (odds ratio 2,47, intervalo confiança 95% 1,65 – 3,71, p < 0,001) associaram-se com a insuficiência cardíaca aguda. A obesidade, a fibrilação auricular, a doença arterial periférica e a doença renal crónica foram identificadas como fatores de risco independentes. Doentes com múltiplas comorbilidades tiveram um risco superior de hospitalização por insuficiência cardíaca: zero comorbilidades – odds ratio 0,43, 95% intervalo confiança 0,28 – 0,67, p < 0,001; uma comorbilidade – odds ratio 0,69, 95% intervalo confiança 0,47 – 1,01, p = 0,057; duas comorbilidades – odds ratio 1,85, 95% intervalo confiança 1,11 – 3,08, p = 0,019; ≥ três comorbilidades – odds ratio 5,81, 95% intervalo confiança 2,77 – 12,16, p < 0,001.

Discussão: Este estudo mostra uma associação entre várias comorbilidades e a hospitalização por insuficiência cardíaca aguda. A associação parece fortalecer-se na presença de múltiplas comorbilidades.

Conclusão: O comorbidoma é uma ferramenta útil para identificar comorbilidades associadas a maior risco de insuficiência cardíaca aguda. A identificação de doentes vulneráveis pode permitir a instituição de intervenções multidimensionais para minimizar hospitalizações futuras.

Palavras-chave: Comorbidade; Hospitalização; Insuficiência Cardíaca; Mortalidade

INTRODUCTION

The incidence of heart failure (HF) has remained stable over the past two decades while survival has improved.1,3 It is estimated that at 45 years, the lifetime risk for HF, at age 75 and 95, ranges from 20% - 30% and 39% - 46%, respectively.4 In Portugal, the age adjusted prevalence of HF varies between 1.4% and 16.1%,5 with an expected increase...
of 30% by 2035 and 33% by 2060.6

Acute HF (aHF) is responsible for nearly one million hospitalizations each year with rising rates7 and, after an initial hospitalization, 25% of patients are readmitted at 30 days, 35% of which due to a new exacerbation.8 Improvements in treatments have improved survival and reduced the hospitalization rate in patients with aHF, although the outcome remains unsatisfactory.9 Moreover, HF care constitutes an increasing economic burden, mainly due to costs related to hospitalizations.6

Whilst the differentiation of the underlying cause of heart disease and identification of precipitating factors of aHF are extremely important, identification and management of associated comorbidities may have an influence in the outcomes. In elderly patients with HF, the prevalence of comorbidities can reach 96%.10 Those with multiple comorbidities are often older and have a higher New York Heart Association (NYHA) class. Several studies have suggested that comorbidities have a significant prognostic role as some of them are predictive of mortality and hospitalization.9,10

aHF is one of the most common diagnoses in patients admitted to Internal Medicine departments,11 where multimorbid patients are extremely prevalent. Only few studies have analysed multiple non-cardiac comorbidities in patients with HF, a minority of which assessed patients admitted to Internal Medicine units.12,13 Our aim is to evaluate the role of comorbidities in patients with aHF in an Internal Medicine unit.

MATERIAL AND METHODS

This study was conducted as a retrospective cohort study. A sample of consecutive patients admitted to an Internal Medicine ward of a tertiary institution (Porto Hospital Medical Centre – Porto – Portugal), in the period 2014 - 2015, was selected. HF diagnosis was presumed after reviewing medical records review for symptoms, natriuretic peptide levels and echocardiographic findings according to European Society of Cardiology guidelines.14 Patients without an echocardiogram were included if relevant heart disease was mentioned in their clinical record and NT-proBNP levels were higher than 1000 pg/mL.

Subjects with aHF and chronic heart failure (cHF) were included, regardless if the former was the main diagnosis or an associated disease. aHF included acute, de novo and chronic decompensated HF and was presumed in the presence of at least two clinical criteria of aggravated peripheral or central congestion (dyspnoea, orthopnoea, paroxysmal nocturnal dyspnoea, venous jugular distension, rales, peripheral oedema, ascites), developed in the last weeks. cHF was presumed in those patients admitted for reasons other than aHF and in the presence of the chronic symptoms stated above or, in its absence, if there was history of HF controlled by appropriate therapy. Patients younger than 18 years were excluded.

Demographic data (age and sex), length of stay (measured in days), number of diagnoses at discharge (codified according to ICD-9), outcomes (in-hospital mortality and readmission at 30 days), heart disease characterization (aetiology and left ventricle ejection fraction) and comorbidities were collected using electronic medical records. Fifteen comorbidities were considered: diabetes, dyslipidaemia, hypertension, hyperuricemia, obesity, atrial fibrillation (AF), peripheral arterial disease (PAD), cerebral vascular disease (CVD), pulmonary thromboembolism (PE), chronic kidney disease (CKD), anaemia, chronic obstructive pulmonary disease (COPD), asthma, obstructive sleep apnea-hypopnea syndrome (OSAHS) and dementia. Comorbidities were considered if the diagnostic criteria listed in international guidelines were met after review of physical examination records, blood tests, ECG, lung and sleep function tests, doppler ultrasound, cognitive tests and/or previous convincing record of the disease.14,15 CKD was defined as stage 3 - 5 KDIGO and glomerular filtration rate was calculated using the basal creatinine level before admission.

Reduced left ventricle ejection fraction was presumed if below 40%, according to the European Society of Cardiology.16

Demographic variables and comorbidities of patients with aHF were compared to those of patients with cHF admitted for other reasons. We considered only comorbidities with a prevalence > 10%. Prolonged hospital stay was presumed if above the median length of stay of Internal Medicine department in 2014-2015.

Baseline continuous data was presented as median ± interquartile range (IQR). Categorical data was presented as absolute and relative frequencies. Patients with aHF and cHF were compared using unpaired t-test, Mann-Whitney test or chi-squared test depending on data type. Uni and multivariate logistic regression analyses (adjusted for age and gender) were used to estimate the odds ratio (OR) and 95% confidence interval (CI) of each comorbidity. Results are visualized as a comorbidome, a graphical representation of the prevalence of comorbidities and their association with the outcome.

A two-tailed p value of less than 0.05 was considered significant. Statistical analysis was performed with IBM SPSS Statistical Software, version 24.0.

The ethics committee of our Hospital centre approved this study.

RESULTS

Of a sample of 839 patients admitted to an Internal Medicine unit, 430 patients had HF. Compared to the non-HF population, patients were significantly older and more frequently female. Length of stay was 8.5 ± 9.0 days in the HF group and 9.0 ± 11 in the non-HF group (p = 0.094). HF patients had a higher number of diagnoses at discharge (15.0 ± 5 vs 9.0 ± 6.0, p < 0.001), as well as more cardiovascular risk factors (2.0 ± 2.0 vs 1.0 ± 2.0, p < 0.001).

Two hundred and twenty-nine patients were diagnosed with aHF and 201 with cHF. The demographic and baseline characteristics are summarized in Table 1. Those with aHF were older (OR 1.04, 95% CI 1.02 - 1.05, p < 0.001) and more often female (OR 2.16, 95% CI 1.46 - 3.19, p < 0.001).
The most common clinical hemodynamic profile was B (wet and dry) (96%). Hypertensive heart disease was the most frequent aetiology, followed by ischemic and valvular heart diseases. Valvular heart disease was associated with aHF (OR 1.61, 95% CI 1.02 - 2.54, p = 0.038). Echocardiogram was available in 320 patients. Reduced left ventricle ejection fraction was observed in 26.3% and was significantly associated with aHF (OR 1.61, 95% CI 1.02 - 2.54, p = 0.038). Echocardiogram was available in 320 patients. Reduced left ventricle ejection fraction was observed in 26.3% and was significantly associated with aHF (OR 1.61, 95% CI 1.02 - 2.54, p = 0.038).

DISCUSSION

This study shows that HF is a prevalent diagnosis amongst patients admitted to an Internal Medicine department, coexisting in more than 50%. Almost half of those have some degree of decompensation during hospitalization. Previous studies, conducted in Internal Medicine departments, have demonstrated that HF is the primary diagnosis in 3.1% of the first admissions, a percentage which increases up to 8.7% for patients with multiple hospital readmissions.17 In the PRECIC study, a cohort of 3746 hospitalized patients in a Portuguese Internal Medicine ward, 16.7% had a HF code in the discharge summaries and in 11.5% aHF was the main diagnosis.18 The prevalence of HF is expected to increase 17% between 2018 and 2035.6

When considering all the diagnoses at discharge, heart diseases represent 37.4%.11 Compared to multiple previously conducted studies, our patients are almost a decade older19-21 and the number of total diagnoses at discharge was higher.11 Our sample is, therefore, representative of the high prevalence of HF and comorbidities in patients admitted to Internal Medicine departments.

There was a higher proportion of older and female patients in the aHF group. It is well known that among patients with aHF there are significant differences in comorbidities, precipitating factors and predictors of in-hospital mortality between genders.20 Nowadays, more than 50% of HF patients have preserved left ventricle ejection fraction (pEF) with a number of community-based studies showing and

Table 1 – Baseline characteristics

<table>
<thead>
<tr>
<th>Demographics</th>
<th>Acute heart failure</th>
<th>Chronic heart failure</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years), median (IQR)</td>
<td>81.0 (13.0)</td>
<td>70.0 (25.0)</td>
<td>&lt; 0.001†</td>
</tr>
<tr>
<td>Female sex, n (%)</td>
<td>154 (67.2)</td>
<td>103 (48.8)</td>
<td>&lt; 0.001*</td>
</tr>
<tr>
<td>Number of diagnoses, median (IQR)</td>
<td>15.0 (6.0)</td>
<td>14.5 (6.0)</td>
<td>0.065†</td>
</tr>
<tr>
<td>Cardiovascular risk factors</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ischemic heart disease, n (%)</td>
<td>78 (34.1)</td>
<td>54 (26.9)</td>
<td>0.134*</td>
</tr>
<tr>
<td>Hypertensive heart disease, n (%)</td>
<td>127 (55.5)</td>
<td>118 (58.7)</td>
<td>0.319*</td>
</tr>
<tr>
<td>Valvular heart disease, n (%)</td>
<td>64 (27.9)</td>
<td>39 (19.4)</td>
<td>0.035*</td>
</tr>
<tr>
<td>Left ventricle ejection fraction &lt; 40%, n (%)</td>
<td>62 (34.4)</td>
<td>22 (15.7)</td>
<td>&lt; 0.001*</td>
</tr>
</tbody>
</table>

IQR: interquartile range; †: chi-squared test; ✱: Mann-Whitney U test.

Table 2 – Prevalence of comorbidities in acute heart failure patients

<table>
<thead>
<tr>
<th>Prevalence</th>
<th>n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypertension, n (%)</td>
<td>184 (80.3)</td>
</tr>
<tr>
<td>Diabetes, n (%)</td>
<td>117 (51.1)</td>
</tr>
<tr>
<td>Dyslipidemia, n (%)</td>
<td>111 (48.5)</td>
</tr>
<tr>
<td>Atrial fibrillation, n (%)</td>
<td>110 (48.0)</td>
</tr>
<tr>
<td>Chronic renal failure, n (%)</td>
<td>109 (47.6)</td>
</tr>
<tr>
<td>Anaemia, n (%)</td>
<td>103 (45.0)</td>
</tr>
<tr>
<td>Obesity, n (%)</td>
<td>53 (23.1)</td>
</tr>
<tr>
<td>Hyperuricemia, n (%)</td>
<td>49 (21.4)</td>
</tr>
<tr>
<td>Dementia, n (%)</td>
<td>46 (20.1)</td>
</tr>
<tr>
<td>Cerebrovascular disease, n (%)</td>
<td>42 (18.3)</td>
</tr>
<tr>
<td>Peripheral artery disease, n (%)</td>
<td>25 (10.9)</td>
</tr>
<tr>
<td>COPD, n (%)</td>
<td>24 (10.5)</td>
</tr>
</tbody>
</table>

COPD: chronic obstructive pulmonary disease.

The most common clinical hemodynamic profile was B (wet and dry) (96%). Hypertensive heart disease was the most frequent aetiology, followed by ischemic and valvular heart diseases. Valvular heart disease was associated with aHF (OR 1.61, 95% CI 1.02 - 2.54, p = 0.038). Echocardiogram was available in 320 patients. Reduced left ventricle ejection fraction was observed in 26.3% and was significantly associated with aHF (OR 1.61, 95% CI 1.02 - 2.54, p = 0.038). Echocardiogram was available in 320 patients. Reduced left ventricle ejection fraction was observed in 26.3% and was significantly associated with aHF (OR 1.61, 95% CI 1.02 - 2.54, p = 0.038).
increasing prevalence. Patients with older age, female sex and additional comorbidities are at an increased risk of pEF. Our study mirrors this reality which is not surprising considering the older age, proportion of female patients and high burden of comorbidities.

According to multiple registries, aHF patients have a constellation of cardiovascular and non-cardiovascular comorbidities. It is estimated that 36% - 42% of the Portuguese population has hypertension. In our cohort, hypertension was the most prevalent risk factor (80%), similar to other studies conducted in aHF.

AF is recognised as a significant comorbidity with the prevalence ranging from 24% - 44%. The prevalence of AF increases with age and is particularly frequent in hypertensive and HF patients. In Internal Medicine departments, the prevalence can be as high as 50%. AF increases with age and is particularly frequent in hypertensive and HF patients. In Internal Medicine departments, the prevalence can be as high as 50%. AF is both a cause and consequence of HF, with complex interactions leading to the impairment of systolic and diastolic function that is not present in patients with sinus rhythm. In the literature, AF is associated with a three-fold increased risk of incident HF, stroke and all-cause of death, especially in women. We found that AF has a strong association with aHF with a persistent impact when adjusted for age, gender and other comorbidities.

Data suggests that non-cardiovascular comorbidities are present in more than 30% of patients with HF. In a Medicare study, nearly 40% of elderly patients with HF had 5 or more noncardiac comorbidities and this group accounted for most total hospital days. Of the non-cardiovascular comorbidities, CKD was present in almost half of the patients and was found to be an independent risk factor for aHF. HF is a known risk factor for renal failure and the same risk factors may contribute to both diseases. The HF Pilot Survey of the EURObservational research programme of the European Society of Cardiology found that CKD was associated with HF hospitalization and 41% of all-cause -mortality could be attributable to this comorbidity. Renal dysfunction may represent a barrier for optimal medical treatment for those with HF and reduced ejection fraction and may limit the clinical response to drugs for the management of congestive symptoms. Early interventions in CKD should be started as soon as possible, especially in patients at high risk of aHF, in the attempt to mitigate this burden.

Cardiovascular risk factors were prevalent, with diabetes and dyslipidaemia affecting almost 50% of patients. Previous studies state that 27% to 45% of aHF patients have diabetes and these present more frequently with acute pulmonary oedema or acute coronary syndrome. Diabetes has been described as a risk factor for hospitalization. Interestingly, in this cohort, diabetes was not more frequent in aHF compared to cHF patients.

Hyperuricemia and obesity were the only cardiovascular risk factors associated with aHF. The former has been demonstrated to be independently associated with mortality and correlates with age, male gender, prior diuretic use and renal failure. Hyperuricemia is a marker of abnormal oxidative metabolism and an inflammatory mediator able to disrupt endothelial function and it has been linked to the development of HF. Additionally, diuretics are known to contribute to hyperuricemia. Being the core therapy to HF congestive symptoms, either in aHF or in the prevention of symptoms in stable cHF, it is not unexpected that patients more prone to decomposition had higher uric acid levels.

Obesity is thought to have a complex interplay in the pathophysiology of HF, on left ventricular structure and function and in the presence of other risk factors for HF, including hypertension and coronary artery disease. It is expected an increase in the risk of HF of 5% for men and 7% for women for each increment of 1 in body-mass index (BMI). Although overweight and mildly obese patients consistently have shown the lowest mortality risk of any BMI group, all cause and cardiovascular mortality rates begin to rise for BMI > 35 kg/m².

Interestingly we did not find an association between CVD and aHF. It is known that the risk of recurrent stroke is about two-fold higher in patients with HF and that clinically
asymptomatic ischemic brain lesions are two to four times more likely in HF patients. In turn, 10% – 24% of stroke patients have HF. While HF, either by inducing hypoperfusion or as a source of emboli, is an established risk factor for stroke, the reverse is not clear. Despite the shared risk factors for stroke and HF, previous cohorts were also unable to associate previous stroke with HF mortality or readmission risk.\textsuperscript{32}

Patients with cHF are at higher risk of developing Alzheimer’s disease and vascular dementia,\textsuperscript{36-40} a reality poorly recognized by physicians.\textsuperscript{41} Neuropsychological performance in HF patients is lower compared to control subjects and a pooled analysis showed that the odds ratio for cognitive impairment was 1.62 (95% CI 1.48 - 1.79, $p < 0.0001$) among subjects with HF. Among older patients with cHF, cognitive dysfunction has been associated with an increase in non-therapeutic adherence, hospital admission and a 5-fold increase in mortality risk.\textsuperscript{42} In our analysis, dementia was inversely associated with aHF. The existence of caregivers, in face of patients unable to secure self-care, could be hypothesised as a way to lower non-therapeutic adherence. However, we believe that this inverse association is not necessarily real. The main diagnosis leading to hospital admission in this population was infection and aHF only occurred in 11% of the demented patients, leading us to the conclusion that this inverse correlation is due to a sampling bias.

Comorbidities influence not only the severity of symptoms and the quality of life, but also the prognosis. It is estimated that 39% of HF patients are hospitalized because of non-cardiovascular comorbid conditions.\textsuperscript{43} In this cohort, 46.7% of cHF patients were admitted for reasons others than aHF. A recent study including 207 984 aHF patients showed that 82% had at least one comorbidity.\textsuperscript{44} These results are in line with our findings. We found that the higher the burden of comorbidities, the higher the association with aHF, with almost a 6-fold increase in the presence of 3 or more comorbidities. It is already known that patients with higher comorbidity burden have an increased risk of readmission and mortality.\textsuperscript{44}
HF is, in fact, a classic example of some potential interactions between several medical conditions. The concept of comorbidome entails a graphic representation of the prevalence and impact of comorbidities in several groups of patients and disease. This disease clustering approach could lead towards the development of new multimorbidity guidelines. This first HF comorbidome could be the first step in the direction of a multimodal approach for the care of HF patients.

Our study has several limitations. First, this is a retrospective evaluation and future analyses of comorbidities-HF interaction should be conducted prospectively, aiming at a larger sample. Second, aHF was not always the main diagnosis for hospitalization and patients with chHF are not an ideal control group as they were admitted due to other acute illnesses. The impact of these diseases was not analysed. However, our aim was to compare inpatients of an Internal Medicine department, with and without aHF, and we not only were expecting this influence as we were interested in it. The selection of an Internal Medicine department might also lead to a selection bias and not be generalizable to the global HF population. Third, some of the associations found illustrate the complexity of patients admitted to Internal Medicine departments. We believe that some comorbidities, not shown to be associated with aHF in this study, might indeed be. Future studies should be more robust in order to confirm the the associations found and uncover others. On the other hand, a cause-effect analysis should be pursued in order to achieve a better understanding of these interplays. Forth, our data had been extracted from a single tertiary hospital. For this reason, we cannot extrapolate our results to other hospitals with different structure or to other departments such as cardiology or geriatrics.

CONCLUSION

Obesity, AF, PAD, CKD were found to be independently associated with aHF. A higher number of comorbidities correlated with aHF admission. Comorbidomes help to phenotype diseases, enhancing unexpected associations and promoting a better understanding about comorbidities and outcomes. Indeed, we believe that a holistic approach of HF patients may stimulate the development of strategies for early intervention on comorbidities in order to prevent re-hospitalizations and limit morbidity, mortality and health care costs.

PROTECTION OF HUMANS AND ANIMALS

The authors declare that the procedures were followed according to the regulations established by the Clinical Research and Ethics Committee and to the Helsinki Declaration of the World Medical Association.

DATA CONFIDENTIALITY

The authors declare having followed the protocols in use at their working center regarding patients’ data publication.

CONFLICTS OF INTEREST

The authors declare that there is no conflict of interests regarding the publication of this paper.

FUNDING SOURCES

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

REFERENCES

acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18:951-975.


